Similar articles

• Comparative evaluation of the safety and efficacy of HMG-CoA reductase inhibitor monotherapy in the treatment of primary hypercholesterolemia.

  Hsu I, Spinler SA, Johnson NE. Hsu I, et al. Ann Pharmacother. 1995 Jul-Aug;29(7-8):743-59. doi: 10.1177/106002809502907-818. Ann Pharmacother. 1995. PMID: 8520093 Review.
• Meeting national cholesterol education goals in clinical practice--a comparison of lovastatin and fluvastatin in primary prevention.

  Nash DT. Nash DT. Am J Cardiol. 1996 Sep 26;78(6A):26-31. doi: 10.1016/s0002-9149(96)00659-5. Am J Cardiol. 1996. PMID: 8875972 Clinical Trial.
• Fluvastatin and cancer.

  Mascitelli L, Pezzetta F. Mascitelli L, et al. Int J Clin Pract. 2007 Jan;61(1):168; author reply 168-9. doi: 10.1111/j.1742-1241.2006.01205.x. Int J Clin Pract. 2007. PMID: 17229191 No abstract available.
• Development of tachyphylaxis among patients taking HMG CoA reductase inhibitors.

  Cromwell WC, Ziajka PE. Cromwell WC, et al. Am J Cardiol. 2000 Nov 15;86(10):1123-7. doi: 10.1016/s0002-9149(00)01171-1. Am J Cardiol. 2000. PMID: 11074211
• [High therapeutic effect and safety of fluvastatin].

  [No authors listed] [No authors listed] Pharm Unserer Zeit. 2003;32(6):516-7. doi: 10.1002/pauz.200390134. Pharm Unserer Zeit. 2003. PMID: 14639833 Review. German. No abstract available.